As access and equity are key tenets of human rights, and with the imperative to ensure that efforts to advance women's health are afforded the important priority they deserve, we believe that we must work to ensure access to our life-saving human papillomavirus (HPV) vaccine, GARDASIL®...and focus special attention on efforts to ensure that it reaches young women living in low income countries where the burden of cervical cancer is greatest...The compelling clinical data of our HPV vaccine have led to regulatory approvals for GARDASIL in over 110 countries around the world, including India and in 2009 became the first cervical cancer vaccine to receive World Health Organization (WHO) pre-qualification...WHO pre-qualification aims to ensure that vaccines meet WHO standards of quality, safety and efficacy...In addition to the work done in our clinical trials, MSD has established a robust surveillance program to monitor the long-term safety, efficacy and duration of protection of people who are vaccinated with GARDASIL.